Sign In
Buy TEVA
$32.83
-0.250 (-0.756%)
At Close: Jun 03, 2026
TEVA's Prolia Biosimilar Gets FDA Nod, Xolair Filing Accepted
01:16pm, Tuesday, 31'st Mar 2026
Teva wins FDA approval for Prolia biosimilar Ponlimsi and secures Xolair biosimilar filing review by the FDA and EMA, strengthening its biosimilars push.
TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demons
E. Ohman J or Asset Management AB Takes Position in Teva Pharmaceutical Industries Ltd. $TEVA
04:07am, Thursday, 26'th Mar 2026
E. Ohman J or Asset Management AB purchased a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) during the fourth quarter, according to its most recent filing with the Securit
Hudson Bay Capital Management LP Acquires 105,000 Shares of Teva Pharmaceutical Industries Ltd. $TEVA
05:16am, Sunday, 22'nd Mar 2026
Hudson Bay Capital Management LP grew its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 87.5% in the undefined quarter, according to its most recent 13F filing with the Securities and E
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
04:30pm, Thursday, 19'th Mar 2026
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quar
Teva Releases Q1 2026 Aide Memoire
04:30pm, Thursday, 19'th Mar 2026
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on
Dow, S&P 500 Set to Snap 4-Day Skid as Oil, Bond Yields Cool
11:50am, Monday, 16'th Mar 2026
Stocks are soaring to start the new week, as falling oil prices and bond yields encourage investors
Capital International Investors Raises Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA
04:13am, Thursday, 12'th Mar 2026
Capital International Investors boosted its stake in Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) by 0.7% in the third quarter, according to the company in its most recent 13F filing with the Secu
FDA Approves Leucovorin—But Not For Autism, Even After Trump Admin Officials Touted Drug Last Year
11:05am, Tuesday, 10'th Mar 2026
The Food and Drug Administration approved the drug leucovorin as a treatment for the rare genetic condition cerebral folate deficiency on Tuesday—but stopped short of approving it as a treatment
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
10:30am, Tuesday, 10'th Mar 2026
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
04:28pm, Monday, 09'th Mar 2026
Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Global Healthcare Conference 2026 Transcript
The 3 Best Stocks to Invest $1,000 in Right Now
02:00pm, Friday, 06'th Mar 2026
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising pr
3 Generic Drug Stocks to Watch Despite Industry Headwinds
10:45am, Wednesday, 04'th Mar 2026
Generic drugmakers face pricing pressure, but companies like TEVA, SDZNY and RDY are betting on complex generics and biosimilars to protect growth.
Form 13Fs help investors track which stocks and exchange-traded funds (ETFs) Wall Street's most successful money managers bought and sold in the latest quarter. Profit-taking looks to have been on bil
Teva and Blackstone Life Sciences Announce $400 Million Strategic Growth Capital Agreement to Advance duvakitug
05:00pm, Tuesday, 03'rd Mar 2026
Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A Duvakitug is currently in phase 3 clinical studies for ulcerative col
